Mr PETER DONALD

TOTAL HEALTH CENTRAL COAST
37 TREELANDS DRIVE
JILLIBY NSW 2259

NutriPATH
Integrative Pathology Services
P: 1300 688 522
E: info@nutripath.com.au
A: PO Box 442 Ashburton VIC 3142

INTEGRATIVE MEDICINE

URINE, SPOT	Result	Range	Units
DETOXIFICATION CAPACITY PROFILE			
PHASE I (OXIDATION)			
Caffeine Clearance	**1.1**	0.5 - 1.6	ml/min/Kg
PHASE II (CONJUGATION)			
Glutathionation	**6.5**	5.6 - 11.4	% Recovery
Glycination	**48.5**	30.0 - 53.0	% Recovery
Sulphation	***15.9*** ***L**	16.0 - 36.0	% Recovery
Glucuronidation	**44.5**	27.0 - 56.0	% Recovery
RATIOS			
PHASE I / PHASE II - Sulphation	**6.9**	3.5 - 13.0	RATIO
PHASE I / PHASE II - Glycination	**2.3**	1.3 - 3.5	RATIO
PHASE I / PHASE II - Glucuronide	**2.5**	1.9 - 4.2	RATIO



(*) Result outside normal reference range

(L) Result is below lower limit of reference range

Mr PETER DONALD

TOTAL HEALTH CENTRAL COAST
37 TREELANDS DRIVE
JILLIBY NSW 2259

NutriPATH
Integrative Pathology Services
P: 1300 688 522
E: info@nutripath.com.au
A: PO Box 442 Ashburton VIC 3142

Liver Detox. Profile Comments

The Detoxification Capacity Profile is a functional test to assess the ability of an individual to process caffeine, aspirin, and paracetamol by assessing certain metabolites in saliva and urine specimens measuring the different phases of liver detoxification.

Adequate Phase I (P450) liver enzyme detoxification activity. Within normal limits.
LOW SULPHATION
(acetaminophen sulphate recovery):

SULPHATION is responsible for the conjugation of steroid hormones (estrogens, progesterone, DHEA), phenols (histamine, Dopamine, gallic acid, coumarin), catecholamines (adrenalin, noradrenalin)

Suspect: Insufficient sulfation/Difficult removal of toxins from the body.

Possible causes:
a) Depletion of inorganic sulphate,
b) Excess exposure to xenobiotics or free radical production,
c) Inadequate dietary sulphate available,
d) Insufficient nutrient cofactors,
e) Induced P450 activity,
f) Impaired sulphoxidation ability (especially if high cysteine/sulphate ratio, with low plasma sulphate),
g) Molybdenum insufficiency, especially if low plasma sulphate,
h) Molybdenum or vitamin B6 excess (can inhibit sulfation),
i) Underlying hepatic disease,
j) Genetic uniqueness,
k) Sulphation may be low if a shared pathway (e.g. glucuronidation) is taking on more compound than usual.

Consider the following actions:
a) Rule out excess xenobiotic exposure, especially if elevated caffeine clearance,
b) Consider foods or supplements containing sulphate precursors, unless high cysteine/sulphate ratio with low plasma sulphate,
c) supplement with: L-methionine, L-cysteine, N-acetylcysteine, Reduced glutathione,
d) Increase intake of nutrient cofactors Zn, Cu, riboflavin, selenium, Mg, vitamin B6, B12, folic acid,
e) Consider inorganic sulphate (especially if high cysteine/sulphate ratio with low plasma sulphate),
f) Increase intake of molybdenum, if signs of insufficiency such as impaired sulphoxidation and/or sulphite toxicity.

Phase I/Phase II Ratios

IF Low, Then
Toxin exposures tend to show higher accrual of tissue levels because clearance is limited by hepatic oxidation.

If High, Then
Risk of carcinogenesis is increased due to higher rates of accumulation of toxic intermediates.

Improve Phase I to Phase II levels accordingly, by upregulating or down regulating phase I or phase II levels.

(*) Result outside normal reference range (L) Result is below lower limit of reference range

P: 1300 688 522
E: info@nutripath.com.au
A: PO Box 442 Ashburton VIC 3142

Mr PETER DONALD

TOTAL HEALTH CENTRAL COAST
37 TREELANDS DRIVE
JILLIBY NSW 2259

Tests ordered: LIVER,IMPEI

Mr PETER DONALD

TOTAL HEALTH CENTRAL COAST
37 TREELANDS DRIVE
JILLIBY NSW 2259

NutriPATH
Integrative Pathology Services
P: 1300 688 522
E: info@nutripath.com.au
A: PO Box 442 Ashburton VIC 3142

The Liver detoxification profile evaluates the ability of an individual to process caffeine, aspirin, and paracetamol by assessing certain metabolites in saliva and urine specimens measuring phases of liver detoxification.

Phase 1, also known as caffeine clearance, bioactivation occurs via oxidation, reduction and hydrolysis, predominantly by the cytochrome p450 enzyme family.

Phase	Causes	Treatment Considerations
High Phase 1 Increased exposure to toxins and production of free radicals.	• Exposure to P450 enzyme inducers - Drugs e.g. barbiturates, HRT, steroids, sulfonamides - Environmental pollutants e.g. exhaust fumes, paint fumes, dioxin & • pesticides - Gut-derived toxins from gut dysbiosis or leaky gut - Others: alcohol, cruciferous vegetables, charcoal-broiled foods, tobacco.	• Assess and remove exposure to any P450 inducing substances • Reduce exposure to environmental toxins • Assess and treat gut dysbiosis and/or intestinal permeability (IP) • Antioxidant supplementation- e.g. acai, selenium, vitamin C & E, zinc • Botanical liver support- e.g. ellagic acid, green tea, silymarin, grapefruit juice
Low Phase 1 Reduced activity of Cytochrome P450 from exposure to: Drugs - benzodiazepines, antihistamines, ketoconazole, H2blockers		• Green tea (catechins) • Turmeric • B group vitamins • Bioflavonoids • Amino acids - Glutathione, glycine, glutamine, cysteine

NutriPATH
Integrative Pathology Services
P: 1300 688 522
E: info@nutripath.com.au
A: PO Box 442 Ashburton VIC 3142

TOTAL HEALTH CENTRAL COAST
37 TREELANDS DRIVE
JILLIBY NSW 2259

Phase	Causes	Treatment Considerations

Low Glucoronidation
 	
Reduced acetaminophen glucuronide recovery.
	• Increased exposure to drugs and xenobiotics requiring glucuronidation
	  - e.g. steroid hormones, oxazepam, carbamates, phenols, aniline
	• Genetic enzyme defect
	  - e.g. Gilbert's disease
	• Medications:
	  - Antibiotics e.g. chloramphenicol, novobiocin
	Nutritional & Metabolic Causes:
	• Decreased energy production or reduced energy from dietary sources
	• Hypothyroidism
	• Insulin resistance
	• Vitamin K excess
	• Upregulation of other Phase II pathways.
		• Discontinue medications which may affect glucuronidation
		• Reduce xenobiotic exposure
		• High quality protein source
		• Support mitochondrial function to help improve energy production
		  - e.g. antioxidants, coQ10, magnesium
		  - Aspartic acid, iron, L-glutamine, magnesium, niacin, vitamin B6
		• Increase cruciferous vegetable intake e.g. watercress
		• Reduce enterohepatic recirculation of toxins e.g. calcium D-glucurate
		• Support other Phase II pathways.

Low Glycination • Reduced salicyluric acid recovery.	• Increased levels of drugs & xenobiotics requiring glycination - e.g. aspirin, benzoate, phenylacetic acid, aliphatic amines • Liver disease • Genetic enzyme defect.	• L-glycine supplementation • Supplement glycination cofactors- cysteine, magnesium, vitamin B5 • Reduce benzoate exposure - e.g. sodium benzoate preservative • Reduce xenobiotic exposure • Reduce salicylate exposure from cosmetics, drugs & diet.

NutriPATH
Integrative Pathology Services
P: 1300 688 522
E: info@nutripath.com.au
A: PO Box 442 Ashburton VIC 3142

TOTAL HEALTH CENTRAL COAST
37 TREELANDS DRIVE
JILLIBY NSW 2259

Phase	Causes	Treatment Considerations
Low Glutathionation: Reduced acetaminophen mercapturate recovery.	• Increased exposure to drugs & xenobiotics requiring glutathionation e.g. acetaminophen, penicillin, tetracycline, styrene, toxic metals, bacterial toxins • Increased reactive oxygen species • Impairment of other Phase II pathways • Genetic enzyme defects • Enhanced bile production (increases mercapturate elimination via the bile).	• Assess and remove exposure to xenobiotics • Glutathione and glutathioine precursor and cofactor supplementation - glutathione, L-glycine, L-glutamine, L-methionine, N-acetylcysteine, • B12, zinc • Botanical liver support supplementation e.g. silymarin, artichoke, watercress • Antioxidant supplementation e.g. vitamin C & E, zinc, selenium, acai • Support other Phase II pathways.
Low Sulfation: Reduced acetaminophen sulfate recovery.	• Increased exposure to drugs & xenobiotics requiring sulfation - e.g. minoxidil, terpines, amines, phenols • Increased reactive oxygen species • Impaired sulfoxidase activity • Molybdenum or vitamin B6 excess (can inhibit sulfation) • Liver disease • Genetic enzyme defects • Upregulation of other Phase II pathways.	• Assess and remove exposure to xenobiotics • Sulfate precursors and cofactor supplementation - glutathione, L-methionine, N-acetylcysteine, zinc • Supplement inorganic sulfate (MSM) and/or molybdenum if inadequate cysteine to sulfate conversion (sulfoxidase activity) is suspected • Reduce dietary phenols and amines.

NutriPATH
Integrative Pathology Services
P: 1300 688 522
E: info@nutripath.com.au
A: PO Box 442 Ashburton VIC 3142

TOTAL HEALTH CENTRAL COAST
37 TREELANDS DRIVE
JILLIBY NSW 2259

High Phase 2 pathways

Use adequate cofactor and nutrient support. This will ensure that these molecules do not become depleted and liver detoxification does not become impaired.

Phase 1: Sulphation

Demonstrates the relationship between Phase I and the sulphation pathway and demonstrates whether the biochemicalload from Phase I is too high.

Phase 1: Glycination

These two ratios reflect the relationship between Phase I and these two conjugation pathways and will demonstrate whether the biochemical load from Phase I is high or low.

Phase 1: Glucuronide

These two ratios reflect the relationship between Phase I and these two conjugation pathways and will demonstrate whether the biochemical load from Phase I is high or low.